Acutus Medical Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Acutus Medical şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-2.0%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-2.0%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Investors Give Acutus Medical, Inc. (NASDAQ:AFIB) Shares A 29% Hiding

Feb 24

Market Cool On Acutus Medical, Inc.'s (NASDAQ:AFIB) Revenues Pushing Shares 43% Lower

Dec 20

Take Care Before Diving Into The Deep End On Acutus Medical, Inc. (NASDAQ:AFIB)

Jul 18

Acutus files for FDA approval of catheter ablation system AcQBlate

Oct 18

Acutus Medical Non-GAAP EPS of -$0.93 misses by $0.17, revenue of $4.1M beats by $0.13M

Aug 11

Acutus Medical sees Q2 revenue above consensus estimate

Jul 21

Acutus Medical, Inc. (NASDAQ:AFIB) Analysts Just Trimmed Their Revenue Forecasts By 25%

Apr 06

Analysts Have Been Trimming Their Acutus Medical, Inc. (NASDAQ:AFIB) Price Target After Its Latest Report

May 15

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: AFIB şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: AFIB şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Acutus Medical Piyasaya Karşı Temettü Getirisi

AFIB temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (AFIB)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.3%
Sektör Ortalaması (Medical Equipment)	1.6%
Analist tahmini (AFIB) (3 yıla kadar)	0%

Önemli Temettü: AFIB şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, AFIB şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: AFIB şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: AFIB herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Acutus Medical Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Nasdaq Files A Form 25 Notification of Delisting with the Securities and Exchange Commission to Complete Acutus Medical, Inc.'s Delisting

Acutus Medical, Inc.(NasdaqCM:AFIB) dropped from NASDAQ Composite Index

Acutus Medical Provides Non-Compliance Update

Acutus Medical, Inc., Annual General Meeting, Jun 13, 2024

New minor risk - Shareholder dilution

New major risk - Negative shareholders equity

Full year 2023 earnings released: US$0.41 loss per share (vs US$1.40 loss in FY 2022)

Investors Give Acutus Medical, Inc. (NASDAQ:AFIB) Shares A 29% Hiding

Acutus Medical, Inc. Announces Board Changes

Market Cool On Acutus Medical, Inc.'s (NASDAQ:AFIB) Revenues Pushing Shares 43% Lower

Acutus Medical, Inc. Announces Chief Executive Officer Changes

Third quarter 2023 earnings released: US$0.45 loss per share (vs US$0.72 loss in 3Q 2022)

Acutus Medical, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Acutus Medical Receives A Letter from Nasdaq Approving the Company’s Application to List Its Securities on the Nasdaq Capital Market

Acutus Medical, Inc. Provides Revenue Guidance for the Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Acutus Medical, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Take Care Before Diving Into The Deep End On Acutus Medical, Inc. (NASDAQ:AFIB)

Acutus Medical, Inc. Announces Executive Changes

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Acutus Medical, Inc. Provides Revenue Guidance for the Year 2023

Acutus Medical Receives Notice from the Nasdaq Regarding Not in Compliance with Listing Rule 5450(a)(1)

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Acutus Medical, Inc. Announces Results from the AcQForce Flutter Study “AcQForce Flutter: Force Sensing RF Ablation with Low Flow Gold Tip Catheter for Typical Flutter”

Acutus Medical, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

Price target increased to US$4.13

Acutus Medical Achieves Eu Mdr Submission Milestone in Sale of Left-Heart Access Portfolio to Medtronic

Acutus Medical, Inc. Announces Full Market Release of Next Generation Software Platform AcQMap 8.5

High number of new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations

Acutus Medical, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Acutus Medical Receives Non-Compliance Notice From Nasdaq

High number of new directors

Acutus Medical, Inc. Announces Submission of Premarket Approval Application for AcQBlate Force Sensing Ablation Catheter & System

Acutus files for FDA approval of catheter ablation system AcQBlate

Glancy Prongay & Murray LLP Appoints Lead Counsel in Securities Class Action Against Acutus Medical, Inc

Acutus Medical, Inc. Announces Board Changes

Consensus forecasts updated

Price target increased to US$3.38

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Acutus Medical Non-GAAP EPS of -$0.93 misses by $0.17, revenue of $4.1M beats by $0.13M

Acutus Medical, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Acutus Medical Announces Approval of its AcQMap System and AcQMap 3D Imaging and Mapping Catheter in Japan

Acutus Medical, Inc. Provides Revenue Guidance for the Second Quarter of 2022

Acutus Medical sees Q2 revenue above consensus estimate

Acutus Medical, Inc. announced that it has received funding from Deerfield Management Company, L.P. Series C

Medtronic plc (NYSE:MDT) completed the acquisition of Left-heart Access Portfolio from Acutus Medical, Inc. (NasdaqGS:AFIB).

Acutus Medical, Inc. Announces FDA Clearance, Commercial Launch of AcQCross Line Extension Compatible with Watchman Delivery System

Acutus Medical Receives Non-Compliance Notice from Nasdaq

Consensus forecasts updated

Acutus Medical, Inc. Completes Enrollment in Ide Trial with Its Acqblate® Force Sensing Ablation System

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$3.50

High number of new directors

Price target decreased to US$4.00

Acutus Medical, Inc. (NASDAQ:AFIB) Analysts Just Trimmed Their Revenue Forecasts By 25%

Consensus revenue estimates fall by 25%

Full year 2021 earnings: EPS exceeds analyst expectations

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Acutus Medical, Inc

Acutus Medical, Inc. Provides Preliminary Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2021

Independent Director recently bought US$151k worth of stock

Third quarter 2021 earnings released: US$0.94 loss per share (vs US$1.95 loss in 3Q 2020)

Price target decreased to US$16.40

Acutus Medical: A Name To Slowly Accumulate

Acutus Medical, Inc. Provides Revenue Guidance for the Year 2021

Second quarter 2021 earnings released: US$1.02 loss per share (vs US$32.24 loss in 2Q 2020)

AcQMap 8, Acutus Medical’s Innovative Suite of Software Upgrades, Receives FDA Clearance and CE Mark

Acutus Medical, Inc.: Paradigm-Shifting Technology At A Shocking Price

Acutus Medical, Inc. has completed a Follow-on Equity Offering in the amount of $77 million.

Acutus Medical, Inc. Provides Earnings Guidance for the Second Quarter Ending June 30, 2021

Acutus Medical, Inc.(NasdaqGS:AFIB) dropped from Russell 3000E Value Index

Acutus Medical Receives FDA Approval to Initiate US Atrial Fibrillation IDE Trial with the AcQBlate® FORCE Sensing Ablation System

Acutus Medical cleared to start atrial fibrillation IDE trial

Analysts Have Been Trimming Their Acutus Medical, Inc. (NASDAQ:AFIB) Price Target After Its Latest Report

First quarter 2021 earnings released: US$1.04 loss per share (vs US$25.83 loss in 1Q 2020)